PUNE, India, October 29, 2015 /PRNewswire/ --

RnRMarketResearch.com announces addition of "Uveitis - Pipeline Review, H2 2015" a new market research report that provides an overview of worldwide Uveitis's therapeutic pipeline development and analysis.

This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H2 2015 pipeline review of Uveitis with 55 market data tables and 16 figures, spread across 196 pages is available at http://www.rnrmarketresearch.com/uveitis-pipeline-review-h2-2015-market-report.html .

Company Profiles discussed in this report include 2-BBB Medicines BV, AbbVie Inc., Aciont Inc., Aldeyra Therapeutics, Inc., Apitope International NV, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Clearside BioMedical, Inc., Effimune SAS, Endocyte, Inc., Enzo Biochem, Inc., EyeGate Pharmaceuticals, Inc., HanAll Biopharma Co., Ltd., Icon Bioscience, Inc., IMMD Inc., Innomedica Ltd., Johnson & Johnson, Kineta, Inc., Neuroptis Biotech, Novartis AG, Ocata Therapeutics, Inc., OncoNOx ApS, Palatin Technologies, Inc., Panoptes Pharma Ges.m.b.H., Pfizer Inc., pSivida Corp., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., SynDevRx, Inc., ThromboGenics NV, TxCell SA, Virogenomics, Inc. and XOMA Corporation.

Drug Profiles discussed in this report cover 2B3-201, abatacept, adalimumab, ATXUV-1, ATXUV-2, B27-PD, celecoxib, Col-Treg, cyclosporine SR, Cytectin, dalazatide, dexamethasone acetate, dexamethasone sodium hosphate, Drug for Chronic Uveitis, Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders, EC-1496, EC-1669, fluocinolone acetonide SR, FR-104, gevokizumab, HL-036, IMD-0354, INV-17, LFG-316, LME-636, lodamin, methotrexate, NOP-3, NS-2, Oligonucleotides to Activate IL-10 for Uveitis, OX-1001, PA-2612, Peptides to Modulate TCR for Uveitis, piclidenoson, PL-8177, plastoquinone decyl triphenylphosphonium bromide, PP-001, PPL-003, Recombinant Enzymes for Uveitis, sarilumab, sirolimus, Small Molecules to Inhibit 5-lipoxygenase for Uveitis, Stem Cell Therapy for Autoimmune Diseases, TG-931, TOP-1288 and triamcinolone acetonide.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Uveitis and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources and pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Uveitis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=425910 .

Another and related research titled Uveitis Global Clinical Trials Review, H1, 2015 includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Read more at on this uveitis clinical trials report at http://www.rnrmarketresearch.com/uveitis-global-clinical-trials-review-h1-2015-market-report.html .

Explore more reports on pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research